Chief Executive’s message for 2023

Jan 13, 2023

This year is very important to FH Europe. On the horizon, we have some key structural changes and significant potential for growth for which we have been preparing for some time … while ensuring that after 3 years of external factors affecting what we do and how we do it, we get more time to plan, co-create, and execute. This means more time to engage, consult and involve our Network members, Patient Ambassadors, advisors and partners.

Thanks to you all, there have been many activities and many successes 2022. Now it is the time to draw lessons from these and to build on them. We have learnt from the Lisbon meeting, that our Network is extremely committed, energized and feeling united to work together towards a joint goal. From the Prague meeting, we know there is political will to support our efforts yet more is needed to become even more effective in our advocacy efforts. Across different activities in 2022, we learnt we have a compelling mission and a very supportive community of organizations and individuals who are keen to help and advocate with us, drive the change and improvements for (better) health of our people and patients, on whose behalf we advocate. Together with the Network and the wider community in Europe – such as the European Alliance for Cardiovascular Health and EURORDIS on, we have created an unprecedented momentum and effectively drawn attention to the needs and urgency to act for cardiovascular health and in the rare diseases space. Both health policy areas important to us – representing people with inherited lipid conditions like FH, HoFH, elevated Lp(a) and FCS.

I am confident that 2023 will be a year of improved communication and exchange, stronger collaboration and cocreation, support and empowerment through sharing and learning. All of which will help us strengthen our community and drive innovation in how health is valued and preserved, prevention is prioritized, and more personalised patient care and support are delivered.

I wish you all lots of health, physical as well as mental, lots of energy, understanding and faith that together we can! We can improve and save lives of people with inherited lipid conditions.

With my warmest regards and thanks to you all,

Magdalena Daccord
Chief Executive, FH Europe

FH Europe is registered as a charity; Charity number 1170731, registered in England and Wales.

FH Europe is registered as a charity; Charity number 1170731, registered in England and Wales.

FH Europe is supported by an educational grant from Amgen Limited, Sanofi, Regeneron, Akcea Therapeutics Inc. and Amryt
Site by: Vovi Web Design